• Novavax, Inc. has reported past first-quarter 2026 results showing revenue of US$139.51 million, down sharply from US$666.66 million a year earlier, and a net loss of US$9.49 million compared with prior net income of US$518.65 million.
• The swing from earnings per share of US$3.22 to a basic loss of US$0.06 highlights how quickly Novavax’s profitability profile has shifted as its business mix changes.
• Next, we’ll examine how this sharp year-on-year revenue drop and move into loss-making territory affects Novavax’s partnership-led investment narrative.

Capitalize on the AI infrastructure supercycle with our selection of the 39 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.

Novavax Investment Narrative Recap

To own Novavax today, you have to believe its shift to an asset-light, partnership-driven model can eventually offset lumpier vaccine demand and partner risk. The sharp Q1 2026 revenue drop to US$139.51 million and return to a small loss do not directly change the timing of the late 2026 COVID‑flu combo readout, but they do sharpen the near-term risk around liquidity and execution if partner milestones arrive more slowly than expected.

Among recent developments, the January 2026 Pfizer license for the Matrix‑M adjuvant stands out as most relevant. The US$30 million upfront recognized in Q1 helps partially cushion the revenue decline and illustrates how Novavax is leaning on licensing deals to fund operations while it waits on potential milestone and royalty streams from Sanofi’s combination vaccines and other partnered programs.

Yet against that promise, investors should be aware that concentrated dependence on a few partners leaves Novavax exposed if commercialization or regulatory timelines slip...

Novavax's narrative projects $348.5 million revenue and $55.9 million earnings by 2028.

Uncover how Novavax's forecasts yield a $13.78 fair value, a 47% upside to its current price.

Exploring Other Perspectives

Before this weak quarter, the most optimistic analysts were still bracing for annual revenue to fall about 34 percent to roughly US$307 million by 2028, highlighting how sharply views can diverge and why it is worth exploring both the upside from partnerships and the risk that partner driven sales underperform these already cautious expectations.

Explore 4 other fair value estimates on Novavax - why the stock might be worth over 6x more than the current price!

The Verdict Is Yours

Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

• A great starting point for your Novavax research is our analysis highlighting 3 key rewards and 4 important warning signs that could impact your investment decision.
• Our free Novavax research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Novavax's overall financial health at a glance.

Seeking Other Investments?

Don't miss your shot at the next 10-bagger. Our latest stock picks just dropped:

• Find 49 companies with promising cash flow potential yet trading below their fair value.
• Outshine the giants: these 19 early-stage AI stocks could fund your retirement.
• The latest GPUs need a type of rare earth metal called Neodymium and there are only 31 companies in the world exploring or producing it. Find the list for free.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.